- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04076098
Locally Delivered Minocycline in Advanced Periodontitis
Efficacy of Locally Delivered Minocycline in Advanced Periodontitis. A Clinico-microbiological Study
Local drug delivery provides higher concentrations in the availability of the drug at the specific infected sites with the advantage of sustained release. Periocline is a long acting , sustained release local drug delivery system consisting of 2% minocycline hydrochloride in an ointment containing microcapsule type particles. Periocline contains 20mg of minocycline in 0.5 gm of gel in a disposable polypropylene applicator (2% minocycline HCl).
Research has yielded promising results with the local application of minocycline in the treatment of periodontal disease, compared with other non-surgical therapies. However, there is scarcity of reports on the use of local delivery agents with respect to new range of putative pathogens in advanced periodontitis, wherein the tissue invasive anaerobic organisms are present and possibly compromised host response, hence resulting in an exaggerated breakdown of periodontal tissues at the affected sites. The effect of Minocycline on new putative pathogens, such as Filifactor alocis and oral phylotypes of phyla Synergistetes and TM7 (referred to hereafter as oral Synergistetes and oral TM7s), has not been investigated yet.
Hence, the aim of the present study is to evaluate the efficacy of a local delivery agent containing minocycline (Periocline, Sunstar, Japan) as an adjunct to SRP in the treatment of deep periodontal pockets around teeth in advanced periodontitis and the antimicrobial effect on the red complex and the new putative pathogens.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Selangor
-
Jenjarum, Selangor, Malaysia, 42610
- Mahsa University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- systematically healthy patients with age range between 20- 60 years,
- diagnosed with untreated Advanced Periodontitis with a pocket depth ≥6mm around two or more teeth, in two or more quadrants.
Exclusion Criteria:
- Patients given antibiotics or anti-inflammatory drugs in the past 6 months,
- allergic to tetracycline,
- pregnant or nursing females,
- those using chlorhexidine or any other mouth rinse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Minocycline
Minocycline gel
|
Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Other Names:
|
Placebo Comparator: Placebo
Similar gel without the active agent
|
Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Probing pocket depth (PPD)
Time Frame: baseline to 12 weeks
|
Periodontal pocket is measured from the gingival margin to the base of the periodontal pocket using a UNC periodontal probe (which is graduated from 1mm to 15mm).
The measurement of periodontal pocket depth is a continuous scale.
PPD is taken at 6 points on each tooth.
The mean of the PPD will be obtained for each patient and subjected to statistical analysis.
|
baseline to 12 weeks
|
Change in the numbers of Periodontal pathogens
Time Frame: baseline to 12 weeks
|
Plaque samples taken from periodontal pockets on paper points will be first stored and later analysed for the presence and number of periopathogens using quantative Polymerase Chain Reaction (q-PCR). The following periodontal pathogens will be assessed:
|
baseline to 12 weeks
|
Clinical Attachment Levels (CAL)
Time Frame: baseline, 6 weeks and 12 weeks
|
change in CAL
|
baseline, 6 weeks and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plaque Index
Time Frame: baseline to 12 weeks
|
change in Plaque scores (Silness and Loe Plaque index, 1964) The score ranges from 0-3 and it is a continuous scale. '0' - no plaque '1' - thin plaque which is not visible by naked eye '2' - Moderate accumulation plaque seen by naked eye '3' - abundance of plaque. Calculation total score /number of surfaces examined = Index score for each patient. Mean plaque score is calculated for all the patients. |
baseline to 12 weeks
|
Bleeding Index
Time Frame: baseline to 12 weeks
|
change in Bleeding scores (Papillary bleeding index, Muehlemann 1977) The score ranges from 0-4 and it is a continuous scale. '0' - no bleeding '1' - Single discrete bleeding point '2' - Single line of blood appears '3' - Interdental papilla fills with blood after probing '4' - profuse bleeding after probing Calculation total score /number of surfaces examined = Index score for each patient. Mean plaque score is calculated for all the patients. |
baseline to 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tara Taiyeb Ali, MSc, FDSRCS, Mahsa University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP139-02/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Periodontitis, Adult
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Research Institute for Genetic and Human TherapyUnknownGeneralized Adult Periodontitis
-
University of SienaNot yet recruitingPeriodontitis, AdultItaly
-
Lithuanian University of Health SciencesCompleted
-
Louisiana State University Health Sciences Center...CompletedPeriodontitis, AdultUnited States
-
University of BergenCompletedPeriodontitis | Adult Periodontitis
-
Cairo UniversityUnknownPeriodontitis, AdultEgypt
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Dr. D. Y. Patil Dental College & HospitalCompletedAdult PeriodontitisIndia
-
Central Hospital, Nancy, FranceCompleted
-
Dexcel Pharma Technologies Ltd.Completed
Clinical Trials on Minocycline Hydrochloride
-
Ain Shams Universityfaculty of pharmacy Tanta UniversityNot yet recruiting
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingIschemic Stroke, AcuteChina
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
Central South UniversityCompleted
-
Ranbaxy Laboratories LimitedCompleted
-
Ranbaxy Laboratories LimitedCompleted
-
Xijing HospitalRecruitingAutoimmune EncephalitisChina
-
Sriram RamaswamyCreighton UniversityCompleted
-
Xijing HospitalXi'an Gaoxin Hospital; Xi'an No.3 Hospital; First People's Hospital of Xianyang; Xi'an XD Group Hospital and other collaboratorsRecruitingIschemic Stroke, Acute | Basilar Artery Occlusion | Minocycline | Endovascular TreatmentChina
-
University of California, DavisThe National Fragile X FoundationCompleted